How Endometriosis Prevalence and Improved Diagnostics Are Powering the Global Endometriosis Market to USD 11.9 Billion by 2035

Endometriosis market was valued at $1.8 billion in 2024 and is projected to reach $6.2 billion by 2035, growing at a CAGR of 11.9% during the forecast period (2025–2035). The global endometriosis market is expanding steadily due to the rising prevalence of the condition and growing awareness among patients, healthcare providers, and advocacy groups. Improved education and reduced stigma around women’s health are encouraging earlier consultations, diagnosis, and long-term disease management.

 Browse the full report description of “Endometriosis Market Size, Share & Trends Analysis Report by Drug Type (Gonadotropins Releasing Hormone Agonists, Non-Steroidal Anti-Inflammatory Drug, Progestin, and Oral Contraceptive Pills) by Diagnosis (Ultrasound, Pelvic Exam, Laparoscopy, Magnetic Resonance Imaging (MRI), Hysteroscopy, and Sonohysterography) by Treatment (Hormonal Therapy, and Pain Management), and Low-Power Wide-Area Network (LPWAN)) and by Distribution Channel (Hospital, Drug Stores, Retail Pharmacies, Mail Order Pharmacies, and E-Commerce ) Forecast Period (2025-2035)” of https://www.omrglobal.com/industry-reports/endometriosis-market

 Simultaneously, advancements in diagnostic techniques—such as non-invasive imaging, biomarker research, and AI-assisted clinical tools—are improving detection accuracy and reducing diagnostic delays. The development of targeted and next-generation hormonal therapies is further enhancing treatment outcomes while addressing unmet needs related to efficacy and tolerability.

Key Developments Highlighting Market Momentum

• 2025: Global health organizations reported increased diagnosis rates of endometriosis, reflecting improved awareness and wider access to gynecological care.
• 2024: Global health organizations reported increased diagnosis rates of endometriosis, reflecting improved awareness and wider access to gynecological care.
• 2025: Biopharmaceutical companies progressed targeted hormonal and non-hormonal therapies through clinical trials, signaling a shift toward more personalized and effective treatment options.

Innovation-Driven and Patient-Centric Approaches

Pharmaceutical and biotech companies are increasingly investing in R&D focused on disease-modifying and targeted hormonal therapies for endometriosis. Industry players are also collaborating with healthcare systems and women’s health organizations to expand awareness programs, improve diagnostic pathways, and support personalized treatment strategies.

Strategic Developments in the Global Endometriosis Market

• In 2025, AbbVie Inc. announced the global launch of its novel endometriosis treatment, featuring targeted hormonal therapy designed to reduce pelvic pain and lesion progression, addressing rising prevalence and unmet therapeutic needs.
• In 2024, Ferring Pharmaceuticals completed the acquisition of a specialized women’s health biotech firm, expanding its endometriosis pipeline with next-generation non-hormonal therapeutics.
• Bayer AG entered a strategic partnership with a leading diagnostics provider to co-develop advanced diagnostic tools and digital health solutions for early detection and personalized monitoring of endometriosis.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Drug Type
• Diagnosis
• Treatment
• Distribution Channel

• Competitive Landscape – AbbVie Inc., AstraZeneca plc, Bayer AG, Pfizer Inc. and Takeda Pharmaceutical Company.

 Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

 Global Endometriosis Market Report Segment

By Drug Type

• Gonadotropins Releasing Hormone Agonists
• Non-Steroidal Anti-Inflammatory Drug
• Progestin
• Oral Contraceptive Pills

By Diagnosis

• Ultrasound
• Pelvic Exam
• Laparoscopy
• Magnetic Resonance Imaging (MRI)
• Hysteroscopy
• Sonohysterography

By Treatment

• Hormonal Therapy
• Pain Management

 By Distribution Channel

• Hospital
• Drug Stores
• Retail Pharmacies
• Mail Order Pharmacies
• E-Commerce

 Global Endometriosis Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

 To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/endometriosis-market